Medtronic’s Hugo still a long way from victor
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
The future of renal denervation
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
Aortic opportunity remains narrow for Abbott
Abbott’s latest aortic valve launch is unlikely to gain it a meaningful slice of the market; meanwhile, Edwards’ attention has switched to tricuspid.
Insulet comes out fighting
Pivotal data on its closed-loop insulin delivery system look good, but Medtronic remains a threat.
Venture-backed medtechs rush for the exit
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
